Brief: Cullinan Therapeutics Inc Cln-978 Shows Favorable Safety Profile With Single Target Doses Up To 30 Μg As Well As Initial Multi-Dose Regimen
06/06/2026 10:32
BRIEF-Cullinan Therapeutics Inc Cln-978 Shows Favorable Safety Profile With Single Target Doses Up To 30 Μg As Well As Initial Multi-Dose Regimen June 6 (Reuters) - Cullinan Therapeutics Inc CGEM.O:
CULLINAN THERAPEUTICS INC -CLN-978 SHOWS FAVORABLE SAFETY PROFILE WITH SINGLE TARGET DOSES UP TO 30 ΜG AS WELL AS INITIAL MULTI-DOSE REGIMEN
Source text: ID:nGNX272hJJ
Further company coverage: CGEM.O
((Reuters.Briefs@thomsonreuters.com;))